Doyoung Kwon, Sung-Mi Kim, Maria Almira Correia. Cytochrome P450 endoplasmic reticulum-associated degradation (ERAD): therapeutic and pathophysiological implications[J]. Acta Pharmaceutica Sinica B, 2020, 10(1): 42-60

Cytochrome P450 endoplasmic reticulum-associated degradation (ERAD): therapeutic and pathophysiological implications
Doyoung Kwona, Sung-Mi Kima, Maria Almira Correiaa,b,c,d
a Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA 94158-2517, USA;
b Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158-2517, USA;
c Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA 94158-2517, USA;
d The Liver Center, University of California San Francisco, San Francisco, CA 94158-2517, USA
The hepatic endoplasmic reticulum (ER)-anchored cytochromes P450 (P450s) are mixedfunction oxidases engaged in the biotransformation of physiologically relevant endobiotics as well as of myriad xenobiotics of therapeutic and environmental relevance. P450 ER-content and hence function is regulated by their coordinated hemoprotein syntheses and proteolytic turnover. Such P450 proteolytic turnover occurs through a process known as ER-associated degradation (ERAD) that involves ubiquitindependent proteasomal degradation (UPD) and/or autophagic-lysosomal degradation (ALD). Herein, on the basis of available literature reports and our own recent findings of in vitro as well as in vivo experimental studies, we discuss the therapeutic and pathophysiological implications of altered P450 ERAD and its plausible clinical relevance. We specifically (i) describe the P450 ERAD-machinery and how it may be repurposed for the generation of antigenic P450 peptides involved in P450 autoantibody pathogenesis in drug-induced acute hypersensitivity reactions and liver injury, or viral hepatitis; (ii) discuss the relevance of accelerated or disrupted P450-ERAD to the pharmacological and/or toxicological effects of clinically relevant P450 drug substrates; and (iii) detail the pathophysiological consequences of disrupted P450 ERAD, contributing to non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) under certain synergistic cellular conditions.
Key words:    Cytochromes P450    Endoplasmic reticulumassociated degradation    CHIP E3 ubiquitin ligase    gp78/AMFR E3 ubiquitin ligase    JNK1    AMPK1    Non-alcoholic fatty liver disease    Non-alcoholic steatohepatitis   
Received: 2019-07-09     Revised: 2019-10-30
DOI: 10.1016/j.apsb.2019.11.002
Funds: We thank Mr. Chris Her for liver cell isolation at the UCSF Liver Center Core on Cell & Tissue Biology, supported by NIDDK Center Grant DK26743. This work was supported by NIH Grants GM44037 and DK26506 (USA) to Maria Almira Correia.
Corresponding author: Maria Almira Correia
Author description:
PDF(KB) Free
Doyoung Kwon
Sung-Mi Kim
Maria Almira Correia

1. Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano P, editor. Cytochrome P450: structure, mechanism and biochemistry. Heidelberg: Springer International Publishing; 2015. p. 523-785.
2. Correia MA. Drug biotransformation. In: Katzung BG, editor. Basic and clinical pharmacology. McGraw Hill & Lange; 2018. p. 56-73.
3. Gonzalez FJ. The molecular biology of cytochrome P450s. Pharmacol Rev 1988;40:243-88.
4. Gonzalez FJ, Liu SY, Yano M. Regulation of cytochrome P450 genes: molecular mechanisms. Pharmacogenetics 1993;3:51-7.
5. Gotoh S, Ohno M, Yoshinari K, Negishi M, Kawajiri K. Nuclear receptor-mediated regulation of cytochrome P450 genes. In: Ortiz de Montellano P, editor. Cytochrome P450: structure, mechanism and biochemistry. Heidelberg: Springer International Publishing; 2015. p. 787-812.
6. Watkins PB, Wrighton SA, Schuetz EG, Maurel P, Guzelian PS. Macrolide antibiotics inhibit the degradation of the glucocorticoidresponsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture. J Biol Chem 1986;261:6264-71.
7. Song BJ, Veech RL, Park SS, Gelboin HV, Gonzalez FJ. Induction of rat hepatic N-nitrosodimethylamine demethylase by acetone is due to protein stabilization. J Biol Chem 1989;264:3568-72.
8. Roberts BJ, Shoaf SE, Jeong KS, Song BJ. Induction of CYP2-1 in liver, kidney, brain and intestine during chronic ethanol administration and withdrawal: evidence that CYP2-1 possesses a rapid phase half-life of 6 hours or less. Biochem Biophys Res Commun 1994;205: 1064-71.
9. Correia MA, Davoll SH, Wrighton SA, Thomas PE. Degradation of rat liver cytochromes P4503Aafter their inactivation by3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine: characterization of the proteolytic system. Arch Biochem Biophys 1992;297:228-38.
10. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997;25:1228-33.
11. Olzmann JA, Kopito RR, Christianson JC. The mammalian endoplasmic reticulum-associated degradation system. Cold Spring Harb Perspect Biol 2013;5:a013185.
12. Christianson JC, Ye Y. Cleaning up in the endoplasmic reticulum: ubiquitin in charge. Nat Struct Mol Biol 2014;21:325-35.
13. Preston GM, Brodsky JL. The evolving role of ubiquitin modification in endoplasmic reticulum-associated degradation. Biochem J 2017;474: 445-69.
14. Correia MA. Cytochrome P450 turnover. Methods Enzymol 1991; 206:315-25.
15. Correia MA. Hepatic cytochrome P450 degradation: mechanistic diversity of the cellular sanitation brigade. Drug Metab Rev 2003;35:107-43.
16. Correia MA, Sadeghi S, Mundo-Paredes E. Cytochrome P450 ubiquitination: branding for the proteolytic slaughter?. Annu Rev Pharmacol Toxicol 2005;45:439-64.
17. Kim SM, Wang Y, Nabavi N, Liu Y, Correia MA. Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame. Drug Metab Rev 2016;48:405-33.
18. Wang HF, Figueiredo Pereira ME, Correia MA. Cytochrome P450 3A degradation in isolated rat hepatocytes: 26S proteasome inhibitors as probes. Arch Biochem Biophys 1999;365:45-53.
19. Faouzi S, Medzihradszky KF, Hefner C, Maher JJ, Correia MA. Characterization of the physiological turnover of native and inactivated cytochromes P450 3A in cultured rat hepatocytes: a role for the cytosolic AAA ATPase p97?. Biochemistry 2007;46:7793-803.
20. Sohn DH, Yun YP, Park KS, Veech RL, Song BJ. Post-translational reduction of cytochrome P450IIE by CCl4, its substrate. Biochem Biophys Res Commun 1991;179:449-54.
21. Roberts BJ. Evidence of proteasome-mediated cytochrome P-450 degradation. J Biol Chem 1997;272:9771-8.
22. Tierney DJ, Haas AL, Koop DR. Degradation of cytochrome P450 2-1: selective loss after labilization of the enzyme. Arch Biochem Biophys 1992;293:9-16.
23. Lee CM, Kim BY, Li L, Morgan ET. Nitric oxide-dependent proteasomal degradation of cytochrome P450 2B proteins. J Biol Chem 2008;283:889-98.
24. Lee CM, Tripathi S, Morgan ET. Nitric oxide-regulated proteolysis of human CYP2B6 via the ubiquitin-proteasome system. Free Radic Biol Med 2017;108:478-86.
25. Von Wachenfeldt C, Johnson EF. Structures of eukaryotic cytochromes P450 enzymes. In: Ortiz de Montellano P, editor. Cytochrome P450: structure, mechanism and biochemistry. New York: Plenum Press; 1995. p. 183-223.
26. von Wachenfeldt C, Richardson TH, Cosme J, Johnson EF. Microsomal P450 2C3 is expressed as a soluble dimer in Escherichia coli following modification of its N-terminus. Arch Biochem Biophys 1997;339:107-14.
27. Zhao J, Zhai B, Gygi SP, Goldberg AL. mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy. Proc Natl Acad Sci U S A 2015;112:15790-7.
28. Ahner A, Brodsky JL. Checkpoints in ER-associated degradation: excuse me, which way to the proteasome?. Trends Cell Biol 2004;14:474-8.
29. Taxis C, Hitt R, Park SH, Deak PM, Kostova Z, Wolf DH. Use of modular substrates demonstrates mechanistic diversity and reveals differences in chaperone requirement of ERAD. J Biol Chem 2003; 278:35903-13.
30. Vashist S, Ng DT. Misfolded proteins are sorted by a sequential checkpoint mechanism of ER quality control. J Cell Biol 2004;165:41-52.
31. Cederbaum AI. CYP2-1dbiochemical and toxicological aspects and role in alcohol-induced liver injury. Mt Sinai J Med 2006;73: 657-72.
32. Bardag-Gorce F, French BA, Nan L, Song H, Nguyen SK, Yong H, et al. CYP2-1 induced by ethanol causes oxidative stress, proteasome inhibition and cytokeratin aggresome (Mallory body-like) formation. Exp Mol Pathol 2006;81:191-201.
33. Porubsky PR, Meneely KM, Scott EE. Structures of human cytochrome P-450 2-1. Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates. J Biol Chem 2008; 283:33698-707.
34. Eliasson E, Mkrtchian S, Halpert JR, Ingelman-Sundberg M. Substrate-regulated, cAMP-dependent phosphorylation, denaturation, and degradation of glucocorticoid-inducible rat liver cytochrome P450 3A1. J Biol Chem 1994;269:18378-83.
35. Liao M, Kang P, Murray BP, Correia MA. Cytochrome P450 degradation and its clinical relevance. In: Lu C, Li AP, editors. Enzyme inhibition in drug discovery & development. Hoboken: John Wiley & Sons; 2010. p. 363-406.
36. Gu J, Weng Y, Zhang QY, Cui H, Behr M, Wu L, et al. Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem 2003;278:25895-901.
37. Henderson CJ, Otto DM, Carrie D, Magnuson MA, McLaren AW, Rosewell I, et al. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 2003;278:13480-6.
38. Goasduff T, Cederbaum AI. NADPH-dependent microsomal electron transfer increases degradation of CYP2-1 by the proteasome complex: role of reactive oxygen species. Arch Biochem Biophys 1999; 370:258-70.
39. Zhukov A, Ingelman-Sundberg M. Relationship between cytochrome P450 catalytic cycling and stability: fast degradation of ethanolinducible cytochrome P450 2-1 (CYP2-1) in hepatoma cells is abolished by inactivation of its electron donor NADPH-cytochrome P450 reductase. Biochem J 1999;340:453-8.
40. Eliasson E, Mkrtchian S, Ingelman-Sundberg M. Hormone-and substrate-regulated intracellular degradation of cytochrome P450 (2-1) involving MgATP-activated rapid proteolysis in the endoplasmic reticulum membranes. J Biol Chem 1992;267: 15765-9.
41. Korsmeyer KK, Davoll S, Figueiredo-Pereira ME, Correia MA. Proteolytic degradation of heme-modified hepatic cytochromes P450: a role for phosphorylation, ubiquitination, and the 26S proteasome?. Arch Biochem Biophys 1999;365:31-44.
42. Wang X, Medzihradszky KF, Maltby D, Correia MA. Phosphorylation of native and heme-modified CYP3A4 by protein kinase C: a mass spectrometric characterization of the phosphorylated peptides. Biochemistry 2001;40:11318-26.
43. Wang Y, Liao M, Hoe N, Acharya P, Deng C, Krutchinsky AN, et al. A role for protein phosphorylation in cytochrome P450 3A4 ubiquitin-dependent proteasomal degradation. J Biol Chem 2009; 284:5671-84.
44. Wang Y, Guan S, Acharya P, Liu Y, Thirumaran RK, Brandman R, et al. Multisite phosphorylation of human liver cytochrome P450 3A4 enhances its gp78-and CHIP-mediated ubiquitination: a pivotal role of its Ser-478 residue in the gp78-catalyzed reaction. Mol Cell Proteomics 2012;11:M111010132.
45. Wang Y, Guan S, Acharya P, Koop DR, Liu Y, Liao M, et al. Ubiquitin-dependent proteasomal degradation of human liver cytochrome P450 2-1: identification of sites targeted for phosphorylation and ubiquitination. J Biol Chem 2011;286:9443-56.
46. Wang Y, Kim SM, Trnka MJ, Liu Y, Burlingame AL, Correia MA. Human liver cytochrome P450 3A4 ubiquitination: molecular recognition by UBC7-gp78 autocrine motility factor receptor and UbcH+CHIP-Hsc70-Hsp40 E2-E3 ubiquitin ligase complexes. J Biol Chem 2015;290:3308-32.
47. Pabarcus MK, Hoe N, Sadeghi S, Patterson C, Wiertz E, Correia MA. CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor receptor, AMFR) and CHIP E3 ligases. Arch Biochem Biophys 2009; 483:66-74.
48. Bays NW, Wilhovsky SK, Goradia A, Hodgkiss-Harlow K, Hampton RY. HRD4/NPL4 is required for the proteasomal processing of ubiquitinated ER proteins. Mol Biol Cell 2001;12:4114-28.
49. Elkabetz Y, Shapira I, Rabinovich E, Bar-Nun S. Distinct steps in dislocation of luminal endoplasmic reticulum-associated degradation substrates: roles of endoplasmic reticulum-bound p97/Cdc48p and proteasome. J Biol Chem 2004;279:3980-9.
50. Zhong X, Shen Y, Ballar P, Apostolou A, Agami R, Fang S. AAA ATPase p97/valosin-containing protein interacts with gp78, a ubiquitin ligase for endoplasmic reticulum-associated degradation. J Biol Chem 2004;279:45676-84.
51. Richly H, Rape M, Braun S, Rumpf S, Hoege C, Jentsch S. A series of ubiquitin binding factors connects CDC48/p97 to substrate multiubiquitylation and proteasomal targeting. Cell 2005;120:73-84.
52. Ye Y, Shibata Y, Kikkert M, van Voorden S, Wiertz E, Rapoport TA. Inaugural article: recruitment of the p97 ATPase and ubiquitin ligases to the site of retrotranslocation at the endoplasmic reticulum membrane. Proc Natl Acad Sci U S A 2005;102:14132-8.
53. Liao M, Faouzi S, Karyakin A, Correia MA. Endoplasmic reticulumassociated degradation of cytochrome P450 CYP3A4 in Saccharomyces cerevisiae: further characterization of cellular participants and structural determinants. Mol Pharmacol 2006;69:1897-904.
54. Acharya P, Liao M, Engel JC, Correia MA. Liver cytochrome P450 3A endoplasmic reticulum-associated degradation: a major role for the p97 AAA ATPase in cytochrome P450 3A extraction into the cytosol. J Biol Chem 2011;286:3815-28.
55. Weissman AM. Regulating protein degradation by ubiquitination. Immunol Today 1997;18:189-98.
56. Weissman AM. Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2001;2:169-78.
57. Pickart CM, Fushman D. Polyubiquitin chains: polymeric protein signals. Curr Opin Chem Biol 2004;8:610-6.
58. Fang S, Weissman AM. A field guide to ubiquitylation. Cell Mol Life Sci 2004;61:1546-61.
59. Pickart CM, Eddins MJ. Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta 2004;1695:55-72.
60. Komander D. The emerging complexity of protein ubiquitination. Biochem Soc Trans 2009;37:937-53.
61. Kim PK, Hailey DW, Mullen RT, Lippincott-Schwartz J. Ubiquitin signals autophagic degradation of cytosolic proteins and peroxisomes. Proc Natl Acad Sci U S A 2008;105:20567-74.
62. Kirkin V, McEwan DG, Novak I, Dikic I. A role for ubiquitin in selective autophagy. Mol Cell 2009;34:259-69.
63. Ishikura S, Weissman AM, Bonifacino JS. Serine residues in the cytosolic tail of the T-cell antigen receptor alpha-chain mediate ubiquitination and endoplasmic reticulum-associated degradation of the unassembled protein. J Biol Chem 2010;285:23916-24.
64. Wang X, Herr RA, Rabelink M, Hoeben RC, Wiertz EJ, Hansen TH. Ube2j2 ubiquitinates hydroxylated amino acids on ER-associated degradation substrates. J Cell Biol 2009;187:655-68.
65. Vosper JM, McDowell GS, Hindley CJ, Fiore-Heriche CS, Kucerova R, Horan I, et al. Ubiquitylation on canonical and noncanonical sites targets the transcription factor neurogenin for ubiquitin-mediated proteolysis. J Biol Chem 2009;284:15458-68.
66. Li W, Tu D, Brunger AT, Ye Y. A ubiquitin ligase transfers preformed polyubiquitin chains from a conjugating enzyme to a substrate. Nature 2007;446:333-7.
67. Li W, Tu D, Li L, Wollert T, Ghirlando R, Brunger AT, et al. Mechanistic insights into active site-associated polyubiquitination by the ubiquitin-conjugating enzyme Ube2g2. Proc Natl Acad Sci U S A 2009;106:3722-7.
68. Kulathu Y, Komander D. Atypical ubiquitylationdthe unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat Rev Mol Cell Biol 2012;13:508-23.
69. Morishima Y, Peng HM, Lin HL, Hollenberg PF, Sunahara RK, Osawa Y, et al. Regulation of cytochrome P450 2-1 by heat shock protein 90-dependent stabilization and CHIP-dependent proteasomal degradation. Biochemistry 2005;44:16333-40.
70. Kim SM, Acharya P, Engel JC, Correia MA. Liver cytochrome P450 3A ubiquitination in vivo by gp78/autocrine motility factor receptor and C-terminus of Hsp70-interacting protein (CHIP) E3 ubiquitin ligases: physiological and pharmacological relevance. J Biol Chem 2010;285:35866-77.
71. Ballinger CA, Connell P, Wu Y, Hu Z, Thompson LJ, Yin LY, et al. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol 1999;19:4535-45.
72. Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ, Hohfeld J, et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 2001;3:93-6.
73. Murata S, Minami Y, Minami M, Chiba T, Tanaka K. CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein. EMBO Rep 2001;2:1133-8.
74. Jiang J, Ballinger CA, Wu Y, Dai Q, Cyr DM, Hohfeld J, et al. CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation. J Biol Chem 2001;276:42938-44.
75. Patterson C, Hohfeld J. Molecular chaperones and the ubiquitinproteasome system. In: Mayer J, Ciechanover A, Rechsteiner M, editors. Protein degradation, vol. 2. Weinheim: Wiley-VCH Verlag GmbH & Co KGaA; 2005. p. 1-30.
76. Pratt WB, Morishima Y, Peng HM, Osawa Y. Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage. Exp Biol Med 2010;235:278-89.
77. Nabi IR, Watanabe H, Silletti S, Raz A. Tumor cell autocrine motility factor receptor. EXS 1991;59:163-77.
78. Fang S, Ferrone M, Yang C, Jensen JP, Tiwari S, Weissman AM. The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum. Proc Natl Acad Sci U S A 2001;98:14422-7.
79. Chen Z, Du S, Fang S. gp78: a multifaceted ubiquitin ligase that integrates a unique protein degradation pathway from the endoplasmic reticulum. Curr Protein Pept Sci 2012;13:414-24.
80. Joshi V, Upadhyay A, Kumar A, Mishra A. Gp78 E3 ubiquitin ligase: essential functions and contributions in proteostasis. Front Cell Neurosci 2017;11:259.
81. Chen B, Mariano J, Tsai YC, Chan AH, Cohen M, Weissman AM. The activity of a human endoplasmic reticulum-associated degradation E3, gp78, requires its Cue domain, RING finger, and an E2-binding site. Proc Natl Acad Sci U S A 2006;103:341-6.
82. Meyer HH, Shorter JG, Seemann J, Pappin D, Warren G. A complex of mammalian ufd1 and npl4 links the AAA-ATPase, p97, to ubiquitin and nuclear transport pathways. Embo J 2000;19:2181-92.
83. Dai RM, Li CC. Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin-proteasome degradation. Nat Cell Biol 2001;3:740-4.
84. Ye Y, Meyer HH, Rapoport TA. The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. Nature 2001; 414:652-6.
85. Jarosch E, Taxis C, Volkwein C, Bordallo J, Finley D, Wolf DH, et al. Protein dislocation from the ER requires polyubiquitination and the AAA-ATPase Cdc48. Nat Cell Biol 2002;4:134-9.
86. Bays NW, Hampton RY. Cdc48-Ufd1-Npl4: stuck in the middle with Ub. Curr Biol 2002;12:R366-71.
87. Tsai B, Ye Y, Rapoport TA. Retro-translocation of proteins from the endoplasmic reticulum into the cytosol. Nat Rev Mol Cell Biol 2002; 3:246-55.
88. Rabinovich E, Kerem A, Frohlich KU, Diamant N, Bar-Nun S. AAAATPase p97/Cdc48p, a cytosolic chaperone required for endoplasmic reticulum-associatedproteindegradation. Mol Cell Biol2002;22:626-34.
89. Ye Y, Meyer HH, Rapoport TA. Function of the p97-Ufd1-Npl4 complex in retrotranslocation from the ER to the cytosol: dual recognition of nonubiquitinated polypeptide segments and polyubiquitin chains. J Cell Biol 2003;162:71-84.
90. Ye Y, Shibata Y, Yun C, Ron D, Rapoport TA. A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol. Nature 2004;429:841-7.
91. Bar-Nun S. The role of p97/Cdc48p in endoplasmic reticulumassociated degradation: from the immune system to yeast. Curr Top Microbiol Immunol 2005;300:95-125.
92. Elsasser S, Finley D. Delivery of ubiquitinated substrates to proteinunfolding machines. Nat Cell Biol 2005;7:742-9.
93. Jentsch S, Rumpf S. Cdc48 (p97): a “molecular gearbox” in the ubiquitin pathway?. Trends Biochem Sci 2007;32:6-11.
94. Leichner GS, Avner R, Harats D, Roitelman J. Dislocation of HMG-CoA reductase and Insig-1, two polytopic endoplasmic reticulum proteins, en route to proteasomal degradation. Mol Biol Cell 2009;20:3330-41.
95. Lipson C, Alalouf G, Bajorek M, Rabinovich E, Atir-Lande A, Glickman M, et al. A proteasomal ATPase contributes to dislocation of endoplasmic reticulum-associated degradation (ERAD) substrates. J Biol Chem 2008;283:7166-75.
96. Ikeda Y, Demartino GN, Brown MS, Lee JN, Goldstein JL, Ye J. Regulated endoplasmic reticulum-associated degradation of a polytopic protein: p97 recruits proteasomes to Insig-1 before extraction from membranes. J Biol Chem 2009;284:34889-900.
97. Morris LL, Hartman IZ, Jun DJ, Seemann J, DeBose-Boyd RA. Sequential actions of the AAA-ATPase valosin-containing protein (VCP)/p97 and the proteasome 19 S regulatory particle in sterolaccelerated, endoplasmic reticulum (ER)-associated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem 2014;289:19053-66.
98. Woodman PG. p97, a protein coping with multiple identities. J Cell Sci 2003;116:4283-90.
99. Wojcik C, Rowicka M, Kudlicki A, Nowis D, McConnell E, Kujawa M, et al. Valosin-containing protein (p97) is a regulator of endoplasmic reticulum stress and of the degradation of N-end rule and ubiquitin-fusion degradation pathway substrates in mammalian cells. Mol Biol Cell 2006;17:4606-18.
100. Dreveny I, Pye VE, Beuron F, Briggs LC, Isaacson RL, Matthews SJ, et al. p97 and close encounters of every kind: a brief review. Biochem Soc Trans 2004;32:715-20.
101. Chou TF, Brown SJ, Minond D, Nordin BE, Li K, Jones AC, et al. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc Natl Acad Sci U S A 2011;108:4834-9.
102. Krick R, Bremer S, Welter E, Schlotterhose P, Muehe Y, Eskelinen EL, et al. Cdc48/p97 and Shp1/p47 regulate autophagosome biogenesis in concert with ubiquitin-like Atg8. J Cell Biol 2010;190:965-73.
103. Huyton T, Pye VE, Briggs LC, Flynn TC, Beuron F, Kondo H, et al. The crystal structure of murine p97/VCP at 3.6A. J Struct Biol 2003; 144:337-48.
104. Isaacson RL, Pye VE, Simpson P, Meyer HH, Zhang X, Freemont PS, et al. Detailed structural insights into the p97-Npl4-Ufd1 interface. J Biol Chem 2007;282:21361-9.
105. Davies JM, Brunger AT, Weis WI. Improved structures of full-length p97, an AAA ATPase: implications for mechanisms of nucleotidedependent conformational change. Structure 2008;16:715-26.
106. Peters JM, Cejka Z, Harris JR, Kleinschmidt JA, Baumeister W. Structural features of the 26 S proteasome complex. J Mol Biol 1993; 234:932-7.
107. Walz J, Erdmann A, Kania M, Typke D, Koster AJ, Baumeister W. 26S proteasome structure revealed by three-dimensional electron microscopy. J Struct Biol 1998;121:19-29.
108. Rechsteiner M, Hoffman L, Dubiel W. The multicatalytic and 26 S proteases. J Biol Chem 1993;268:6065-8.
109. Rechsteiner MC. Ubiquitin-mediated proteolysis: an ideal pathway for systems biology analysis. Adv Exp Med Biol 2004;547:49-59.
110. Pickart CM, Cohen RE. Proteasomes and their kin: proteases in the machine age. Nat Rev Mol Cell Biol 2004;5:177-87.
111. Rechsteiner M. The 26S proteasome. In: Mayer J, Ciechanover A, Rechsteiner M, editors. Protein degradation, vol. 1. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2005. p. 220-47.
112. Rechsteiner M, Hill CP. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol 2005;15:27-33.
113. Bedford L, Paine S, Sheppard PW, Mayer RJ, Roelofs J. Assembly, structure, and function of the 26S proteasome. Trends Cell Biol 2010; 20:391-401.
114. Park S, Roelofs J, Kim W, Robert J, Schmidt M, Gygi SP, et al. Hexameric assembly of the proteasomal ATPases is templated through their C termini. Nature 2009;459:866-70.
115. Tomko Jr RJ, Funakoshi M, Schneider K, Wang J, Hochstrasser M. Heterohexameric ring arrangement of the eukaryotic proteasomal ATPases: implications for proteasome structure and assembly. Mol Cell 2010;38:393-403.
116. Ruschak AM, Religa TL, Breuer S, Witt S, Kay LE. The proteasome antechamber maintains substrates in an unfolded state. Nature 2010; 467:868-71.
117. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994;78:761-71.
118. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995; 268:726-31.
119. Dick LR, Cruikshank AA, Destree AT, Grenier L, McCormack TA, Melandri FD, et al. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J Biol Chem 1997;272:182-8.
120. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A 1999;96: 10403-8.
121. Baljevic M, Orlowski RZ. Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma. Expert Opin Drug Metab Toxicol 2019;15:459-73.
122. Raynes R, Pomatto LC, Davies KJ. Degradation of oxidized proteins by the proteasome: distinguishing between the 20S, 26S, and immunoproteasome proteolytic pathways. Mol Aspects Med 2016;50:41-55.
123. Shringarpure R, Grune T, Mehlhase J, Davies KJ. Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J Biol Chem 2003;278:311-8.
124. Pickering AM, Davies KJ. Differential roles of proteasome and immunoproteasome regulators Pa28alphabeta, Pa28gamma and Pa200 in the degradation of oxidized proteins. Arch Biochem Biophys 2012;523:181-90.
125. Michalek MT, Grant EP, Gramm C, Goldberg AL, Rock KL. A role for the ubiquitin-dependent proteolytic pathway in MHC class Irestricted antigen presentation. Nature 1993;363:552-4.
126. Monaco JJ. Pathways for the processing and presentation of antigens to T cells. J Leukoc Biol 1995;57:543-7.
127. Kloetzel PM. Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2001;2:179-87.
128. Kloetzel PM. Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII. Nat Immunol 2004;5:661-9.
129. Monaco JJ, Nandi D. The genetics of proteasomes and antigen processing. Annu Rev Genet 1995;29:729-54.
130. Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 2004;16:76-81.
131. Kloetzel PM. The proteasome and MHC class I antigen processing. Biochim Biophys Acta 2004;1695:225-33.
132. Kimura H, Caturegli P, Takahashi M, Suzuki K. New insights into the function of the immunoproteasome in immune and nonimmune cells. J Immunol Res 2015. Available from: https// 541984.
133. Cascio P, Call M, Petre BM, Walz T, Goldberg AL. Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes. EMBO J 2002;21:2636-45.
134. Kopp F, Dahlmann B, Kuehn L. Reconstitution of hybrid proteasomes from purified PA700-20 S complexes and PA28alphabeta activator: ultrastructure and peptidase activities. J Mol Biol 2001; 313:465-71.
135. Wang X, Yen J, Kaiser P, Huang L. Regulation of the 26S proteasome complex during oxidative stress. Sci Signal 2010;3:ra88.
136. Grune T, Catalgol B, Licht A, Ermak G, Pickering AM, Ngo JK, et al. HSP70 mediates dissociation and reassociation of the 26S proteasome during adaptation to oxidative stress. Free Radic Biol Med 2011;51:1355-64.
137. Reinheckel T, Sitte N, Ullrich O, Kuckelkorn U, Davies KJ, Grune T. Comparative resistance of the 20S and 26S proteasome to oxidative stress. Biochem J 1998;335:637-42.
138. Reinheckel T, Ullrich O, Sitte N, Grune T. Differential impairment of 20S and 26S proteasome activities in human hematopoietic K562 cells during oxidative stress. Arch Biochem Biophys 2000;377:65-8.
139. Kim SM, Grenert JP, Patterson C, Correia MA. CHIPe/e-mouse liver: adiponectin-AMPK-FOXO-activation overrides CYP2-1-elicited JNK1-activation, delaying onset of NASH: therapeutic implications. Sci Rep 2016;6:29423.
140. Kwon D, Kim S-M, Jacob 3rd P, Liu Y, Correia MA. Induction via functional protein stabilization of hepatic cytochromes P450 upon gp78/autocrine motility factor receptor (AMFR) ubiquitin E3-ligase genetic ablation in mice: therapeutic and toxicological relevance. Mol Pharmacol 2019;96:641-54.
141. Masaki R, Yamamoto A, Tashiro Y. Cytochrome P-450 and NADPHcytochrome P-450 reductase are degraded in the autolysosomes in rat liver. J Cell Biol 1987;104:1207-15.
142. Ronis MJ, Johansson I, Hultenby K, Lagercrantz J, Glaumann H, Ingelman-Sundberg M. Acetone-regulated synthesis and degradation of cytochrome P450-1 and cytochrome P4502B1 in rat liver [corrected]. Eur J Biochem 1991;198:383-9.
143. Murray BP, Zgoda VG, Correia MA. Native CYP2C11: heterologous expression in Saccharomyces cerevisiae reveals a role for vacuolar proteases rather than the proteasome system in the degradation of this endoplasmic reticulum protein. Mol Pharmacol 2002; 61:1146-53.
144. Liao M, Zgoda VG, Murray BP, Correia MA. Vacuolar degradation of rat liver CYP2B1 in Saccharomyces cerevisiae: further validation of the yeast model and structural implications for the degradation of mammalian endoplasmic reticulum P450 proteins. Mol Pharmacol 2005;67:1460-9.
145. Dikic I. Proteasomal and autophagic degradation systems. Annu Rev Biochem 2017;86:193-224.
146. Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, et al. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol 2005;169:425-34.
147. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008;451:1069-75.
148. Klionsky DJ, Codogno P, Cuervo AM, Deretic V, Elazar Z, FueyoMargareto J, et al. A comprehensive glossary of autophagy-related molecules and processes. Autophagy 2010;6:438-48.
149. Cuervo AM. Cell biology. Autophagy’s top chef. Science 2011;332: 1392-3.
150. Bento CF, Renna M, Ghislat G, Puri C, Ashkenazi A, Vicinanza M, et al. Mammalian autophagy: how does it work?. Annu Rev Biochem 2016;85:685-713.
151. Lamark T, Svenning S, Johansen T. Regulation of selective autophagy: the p62/SQSTM1 paradigm. Essays Biochem 2017;61: 609-24.
152. Lamark T, Perander M, Outzen H, Kristiansen K, Overvatn A, Michaelsen E, et al. Interaction codes within the family of mammalian Phox and Bem1p domain-containing proteins. J Biol Chem 2003;278:34568-81.
153. Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW. Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 2004;24:8055-68.
154. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 2007;282:24131-45.
155. Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, Hara T, et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 2007;131:1149-63.
156. Lamark T, Kirkin V, Dikic I, Johansen T. NBR1 and p62 as cargo receptors for selective autophagy of ubiquitinated targets. Cell Cycle 2009;8:1986-90.
157. Linares JF, Duran A, Yajima T, Pasparakis M, Moscat J, DiazMeco MT. K63 polyubiquitination and activation of mTOR by the p62-TRAF6 complex in nutrient-activated cells. Mol Cell 2013;51:283-96.
158. Birgisdottir AB, Lamark T, Johansen T. The LIR motifdcrucial for selective autophagy. J Cell Sci 2013;126:3237-47.
159. Dice JF, Terlecky SR, Chiang HL, Olson TS, Isenman LD, ShortRussell SR, et al. A selective pathway for degradation of cytosolic proteins by lysosomes. Semin Cell Biol 1990;1:449-55.
160. Cuervo AM, Dice JF. A receptor for the selective uptake and degradation of proteins by lysosomes. Science 1996;273:501-3.
161. Arndt V, Dick N, Tawo R, Dreiseidler M, Wenzel D, Hesse M, et al. Chaperone-assisted selective autophagy is essential for muscle maintenance. Curr Biol 2010;20:143-8.
162. Gamerdinger M, Kaya AM, Wolfrum U, Clement AM, Behl C. BAG3 mediates chaperone-based aggresome-targeting and selective autophagy of misfolded proteins. EMBO Rep 2011;12:149-56.
163. Kruse KB, Brodsky JL, McCracken AA. Characterization of an ERAD gene as VPS30/ATG6 reveals two alternative and functionally distinct protein quality control pathways: one for soluble Z variant of human alpha-1 proteinase inhibitor (A1PiZ) and another for aggregates of A1PiZ. Mol Biol Cell 2006;17:203-12.
164. Yang H, Ni HM, Guo F, Ding Y, Shi YH, Lahiri P, et al. Sequestosome 1/p62 protein is associated with autophagic removal of excess hepatic endoplasmic reticulum in mice. J Biol Chem 2016;291:18663-74.
165. Stolz A, Ernst A, Dikic I. Cargo recognition and trafficking in selective autophagy. Nat Cell Biol 2014;16:495-501.
166. Khaminets A, Heinrich T, Mari M, Grumati P, Huebner AK, Akutsu M, et al. Regulation of endoplasmic reticulum turnover by selective autophagy. Nature 2015;522:354-8.
167. Khaminets A, Behl C, Dikic I. Ubiquitin-dependent and independent signals in selective autophagy. Trends Cell Biol 2016;26:6-16.
168. Chien JY, Thummel KE, Slattery JT. Pharmacokinetic consequences of induction of CYP2-1 by ligand stabilization. Drug Metab Dispos 1997;25:1165-75.
169. Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, et al. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitroein vivo extrapolation. Curr Drug Metab 2006;7:315-34.
170. Kalgutkar AS, Obach RS, Maurer TS. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structureeactivity relationships and relationship to clinical drugedrug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 2007;8:407-47.
171. Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, et al. Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 2008;9:384-94.
172. Fuhr U. Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf 1998;18:251-72.
173. Bailey DG, Dresser G, Arnold JM. Grapefruit-medication interactions: forbidden fruit or avoidable consequences?. Can Med Assoc J 2013;185:309-16.
174. Bandiera S, Weidlich S, Harth V, Broede P, Ko Y, Friedberg T. Proteasomal degradation of human CYP1B1: effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression. Mol Pharmacol 2005;67:435-43.
175. Beaune P, Dansette PM, Mansuy D, Kiffel L, Finck M, Amar C, et al. Human anti-endoplasmic reticulum autoantibodies appearing in a druginduced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci U S A 1987;84:551-5.
176. Beaune P, Pessayre D, Dansette P, Mansuy D, Manns M. Autoantibodies against cytochromes P450: role in human diseases. Adv Pharmacol 1994;30:199-245.
177. Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the “danger hypothesis” and innate immune system. Chem Res Toxicol 1999;12:387-95.
178. Boitier E, Beaune P. Xenobiotic-metabolizing enzymes as autoantigens in human autoimmune disorders. An update. Clin Rev Allergy Immunol 2000;18:215-39.
179. Uetrecht J. Current trends in drug-induced autoimmunity. Autoimmun Rev 2005;4:309-14.
180. Bourdi M, Gautier JC, Mircheva J, Larrey D, Guillouzo A, Andre C, et al. Anti-liver microsomes autoantibodies and dihydralazineinduced hepatitis: specificity of autoantibodies and inductive capacity of the drug. Mol Pharmacol 1992;42:280-5.
181. Loeper J, Descatoire V, Maurice M, Beaune P, Belghiti J, Houssin D, et al. Cytochromes P-450 in human hepatocyte plasma membrane: recognition by several autoantibodies. Gastroenterology 1993;104: 203-16.
182. Bourdi M, Chen W, Peter RM, Martin JL, Buters JT, Nelson SD, et al. Human cytochrome P450 2-1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 1996;9:1159-66.
183. Eliasson E, Kenna JG. Cytochrome P450 2-1 is a cell surface autoantigen in halothane hepatitis. Mol Pharmacol 1996;50:573-82.
184. Clot P, Albano E, Eliasson E, Tabone M, Arico S, Israel Y, et al. Cytochrome P4502-1 hydroxyethyl radical adducts as the major antigen in autoantibody formation among alcoholics. Gastroenterology 1996;111:206-16.
185. Clot P, Bellomo G, Tabone M, Arico S, Albano E. Detection of antibodies against proteins modified by hydroxyethyl free radicals in patients with alcoholic cirrhosis. Gastroenterology 1995;108: 201-7.
186. Lytton SD, Helander A, Zhang-Gouillon ZQ, Stokkeland K, Bordone R, Arico S, et al. Autoantibodies against cytochromes P-4502-1 and P-4503A in alcoholics. Mol Pharmacol 1999;55: 223-33.
187. Leeder JS, Gaedigk A, Lu X, Cook VA. Epitope mapping studies with human anti-cytochrome P450 3A antibodies. Mol Pharmacol 1996;49:234-43.
188. Robin MA, Le Roy M, Descatoire V, Pessayre D. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in druginduced hepatitis. J Hepatol 1997;26:23-30.
189. Robin MA, Maratrat M, Le Roy M, Le Breton FP, Bonierbale E, Dansette P, et al. Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera. J Clin Invest 1996;98:1471-80.
190. Lytton SD, Berg U, Nemeth A, Ingelman-Sundberg M. Autoantibodies against cytochrome P450s in sera of children treated with immunosuppressive drugs. Clin Exp Immunol 2002;127:293-302.
191. Thervet E, Legendre C, Beaune P, Anglicheau D. Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 2005;6:37-47.
192. Metushi IG, Sanders C, Acute Liver Study G, Lee WM, Uetrecht J. Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. Hepatology 2014;59: 1084-93.
193. Timbrell JA, Mitchell JR, Snodgrass WR, Nelson SD. Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo. J Pharmacol Exp Ther 1980;213:364-9.
194. Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 1989;83: 1066-72.
195. Choudhuri K, Mieli-Vergani G, Vergani D. Cytochrome P4502D6: understanding an autoantigen. Clin Exp Immunol 1997;108:381-3.
196. Winqvist O, Gustafsson J, Rorsman F, Karlsson FA, Kampe O. Two different cytochrome P450 enzymes are the adrenal antigens in autoimmune polyendocrine syndrome type I and Addison’s disease. J Clin Invest 1993;92:2377-85.
197. Winqvist O, Karlsson FA, Kampe O. 21-Hydroxylase, a major autoantigen in idiopathic Addison’s disease. Lancet 1992;339: 1559-62.
198. Krohn K, Uibo R, Aavik E, Peterson P, Savilahti K. Identification by molecular cloning of an autoantigen associated with Addison’s disease as steroid 17 alpha-hydroxylase. Lancet 1992;339:770-3.
199. He K, Bornheim LM, Falick AM, Maltby D, Yin H, Correia MA. Identification of the heme-modified peptides from cumene hydroperoxide-inactivated cytochrome P450 3A4. Biochemistry 1998;37:17448-57.
200. Jiang J, Stoyanovsky DA, Belikova NA, Tyurina YY, Zhao Q, Tungekar MA, et al. A mitochondria-targeted triphenylphosphoniumconjugated nitroxide functions as a radioprotector/mitigator. Radiat Res 2009;172:706-17.
201. Gaude H, Aznar N, Delay A, Bres A, Buchet-Poyau K, Caillat C, et al. Molecular chaperone complexes with antagonizing activities regulate stability and activity of the tumor suppressor LKB1. Oncogene 2012;31:1582-91.
202. Greer EL, Oskoui PR, Banko MR, Maniar JM, Gygi MP, Gygi SP, et al. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J Biol Chem 2007;282:30107-19.
203. Webb AE, Brunet A. FOXO transcription factors: key regulators of cellular quality control. Trends Biochem Sci 2014;39:159-69.
204. van der Horst A, Burgering BM. Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol 2007;8:440-50.
205. Tikhanovich I, Cox J, Weinman SA. Forkhead box class O transcription factors in liver function and disease. J Gastroenterol Hepatol 2013;28:125-31.
206. Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, Takekawa S, et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 2004;279:30817-22.
207. de Keizer PL, Burgering BM, Dansen TB. Forkhead box O as a sensor, mediator, and regulator of redox signaling. Antioxid Redox Signal 2011;14:1093-106.
208. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012;13:251-62.
209. Merrill GF, Kurth EJ, Hardie DG, Winder WW. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol 1997;273:E1107-12.
210. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007;13:332-9.
211. Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A 2007;104: 12017-22.
212. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8: 1288-95.
213. Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca2+ and AMPK/SIRT1. Nature 2010;464: 1313-9.
214. Xiong X, Tao R, DePinho RA, Dong XC. The autophagy-related gene 14 (Atg14) is regulated by forkhead box O transcription factors and circadian rhythms and plays a critical role in hepatic autophagy and lipid metabolism. J Biol Chem 2012;287:39107-14.
215. Kamei Y, Mizukami J, Miura S, Suzuki M, Takahashi N, Kawada T, et al. A forkhead transcription factor FKHR up-regulates lipoprotein lipase expression in skeletal muscle. FEBS Lett 2003;536:232-6.
216. Han Y, Hu Z, Cui A, Liu Z, Ma F, Xue Y, et al. Post-translational regulation of lipogenesis via AMPK-dependent phosphorylation of insulin-induced gene. Nat Commun 2019;10:623.
217. Czaja MJ. JNK regulation of hepatic manifestations of the metabolic syndrome. Trends Endocrinol Metab 2010;21:707-13.
218. Seki E, Brenner DA, Karin M. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology 2012;143:307-20.
219. Farrell GC, van Rooyen D, Gan L, Chitturi S. NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut Liver 2012;6:149-71.
220. Duwaerts CC, Maher JJ. Mechanisms of liver injury in non-alcoholic steatohepatitis. Curr Hepatol Rep 2012;13:119-29.
221. Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med 2015;240:809-20.
222. Ariz U, Mato JM, Lu SC, Martinez Chantar ML. Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new?. Methods Mol Biol 2010;593:109-36.
223. Maher JJ. New insights from rodent models of fatty liver disease. Antioxid Redox Signal 2011;15:535-50.
224. Dekker MJ, Su Q, Baker C, Rutledge AC, Adeli K. Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome. Am J Physiol Endocrinol Metab 2010; 299:E685-94.
225. Ishimoto T, Lanaspa MA, Rivard CJ, Roncal-Jimenez CA, Orlicky DJ, Cicerchi C, et al. High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology 2013;58:1632-43.
226. Lanaspa MA, Ishimoto T, Li N, Cicerchi C, Orlicky DJ, Ruzycki P, et al. Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome. Nat Commun 2013;4:2434.
227. Jensen T, Abdelmalek MF, Sullivan S, Nadeau KJ, Green M, Roncal C, et al. Fructose and sugar: a major mediator of nonalcoholic fatty liver disease. J Hepatol 2018;6:1063-75.
228. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011;13:376-88.
229. Liu TF, Tang JJ, Li PS, Shen Y, Li JG, Miao HH, et al. Ablation of gp78 in liver improves hyperlipidemia and insulin resistance by inhibiting SREBP to decrease lipid biosynthesis. Cell Metab 2012; 16:213-25.
230. Liang JS, Kim T, Fang S, Yamaguchi J, Weissman AM, Fisher EA, et al. Overexpression of the tumor autocrine motility factor receptor Gp78, a ubiquitin protein ligase, results in increased ubiquitinylation and decreased secretion of apolipoprotein B100 in HepG2 cells. J Biol Chem 2003;278:23984-8.
231. Zhang T, Kho DH, Wang Y, Harazono Y, Nakajima K, Xie Y, et al. Gp78, an E3 ubiquitin ligase acts as a gatekeeper suppressing nonalcoholic steatohepatitis (NASH) and liver cancer. PLoS One 2015;10:e0118448.
232. Ni HM, Bockus A, Boggess N, Jaeschke H, Ding WX. Activation of autophagy protects against acetaminophen-induced hepatotoxicity. Hepatology 2012;55:222-32.
233. Ni HM, Jaeschke H, Ding WX. Targeting autophagy for druginduced hepatotoxicity. Autophagy 2012;8:709-10.
234. Ni HM, Boggess N, McGill MR, Lebofsky M, Borude P, Apte U, et al. Liver-specific loss of Atg5 causes persistent activation of Nrf2 and protects against acetaminophen-induced liver injury. Toxicol Sci 2012;127:438-50.
235. Wu D, Cederbaum AI. Inhibition of autophagy promotes CYP2-1-dependent toxicity in HepG2 cells via elevated oxidative stress, mitochondria dysfunction and activation of p38 and JNK MAPK. Redox Biol 2013;1:552-65.
236. Platt FM, Boland B, van der Spoel AC. The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J Cell Biol 2012;199:723-34.
237. Czaja MJ. Functions of autophagy in hepatic and pancreatic physiology and disease. Gastroenterology 2011;140:1895-908.
238. Sun H, Lee CM, Tripathi S, Kim KB, Morgan ET. Nitric oxidedependent CYP2B degradation is potentiated by a cytokineregulated pathway and utilizes the immunoproteasome subunit LMP2. Biochem J 2012;445:377-82.
239. Handa P, Maliken BD, Nelson JE, Morgan-Stevenson V, Messner DJ, Dhillon BK, et al. Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis. Hepatology 2014;60:133-45.
240. Takaki A, Kawai D, Yamamoto K. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). Int J Mol Sci 2014;15:7352-79.
241. Park TJ, Reznick J, Peterson BL, Blass G, Omerbasic D, Bennett NC, et al. Fructose-driven glycolysis supports anoxia resistance in the naked mole-rat. Science 2017;356:307-11.
242. Softic S, Cohen DE, Kahn CR. Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. Dig Dis Sci 2016;61:1282-93.